Log In
Print
BCIQ
Print
Print this Print this
 

ertugliflozin (MK-8835, PF-04971729, PF-4971729)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionOral sodium-glucose cotransporter 2 (SGLT2) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner Merck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$60.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today